keyword
MENU ▼
Read by QxMD icon Read
search

Antipsychotic Weight Gain

keyword
https://www.readbyqxmd.com/read/29775565/a-role-of-neuropeptide-cart-in-hyperphagia-and-weight-gain-induced-by-olanzapine-treatment-in-rats
#1
Kartik T Nakhate, Nishikant K Subhedar, Dadasaheb M Kokare
Although olanzapine is highly efficacious and most widely used second generation antipsychotic drug, the success of treatment has been hampered by its propensity to induce weight gain. While the underlying neuronal mechanisms are unclear, their elucidation may help to target alternative pathways regulating energy balance. The present study was undertaken to define the role of cocaine- and amphetamine-regulated transcript (CART), a well-known anorexic peptide, in olanzapine-induced hyperphagia and body weight gain in rats...
May 15, 2018: Brain Research
https://www.readbyqxmd.com/read/29740394/metabolic-syndrome-and-antipsychotics-the-role-of-mitochondrial-fission-fusion-imbalance
#2
Andrea Del Campo, Catalina Bustos, Carolina Mascayano, Claudio Acuña-Castillo, Rodrigo Troncoso, Leonel E Rojo
Second-generation antipsychotics (SGAs) are known to increase cardiovascular risk through several physiological mechanisms, including insulin resistance, hepatic steatosis, hyperphagia, and accelerated weight gain. There are limited prophylactic interventions to prevent these side effects of SGAs, in part because the molecular mechanisms underlying SGAs toxicity are not yet completely elucidated. In this perspective article, we introduce an innovative approach to study the metabolic side effects of antipsychotics through the alterations of the mitochondrial dynamics, which leads to an imbalance in mitochondrial fusion/fission ratio and to an inefficient mitochondrial phenotype of muscle cells...
2018: Frontiers in Endocrinology
https://www.readbyqxmd.com/read/29718602/treating-bipolar-disorder-in-adolescents
#3
Robert L Findling
How do you select among treatments for bipolar disorder in adolescents? Check out this brief report activity to explore the efficacy and safety of lithium, anticonvulsants, and atypical antipsychotics in the treatment of adolescent bipolar disorder. Plus, receive guidance for monitoring for common adverse effects, such as weight gain and fatigue.
March 2018: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/29715374/aripiprazole-induced-neutropenia-case-report-and-literature-review
#4
Tricia Felin, Sadiq Naveed, Amna M Chaudhary
Aripiprazole is a third-generation atypical antipsychotic medication, which is widely used for various psychiatric disorders across the lifespan. Aripiprazole can cause side effects including headache, insomnia, agitation, nervousness, lightheadedness, dizziness, somnolence, akathisia, and weight gain. Neutropenia is a less frequent side effect of aripiprazole. The current article reviews a case of a 10-year-old African American boy who developed neutropenia with aripiprazole. It is important for clinicians to be aware of this rare side effect...
May 1, 2018: Journal of Psychosocial Nursing and Mental Health Services
https://www.readbyqxmd.com/read/29713286/the-wnt-signaling-pathway-effector-tcf7l2-mediates-olanzapine-induced-weight-gain-and-insulin-resistance
#5
Ranran Li, Jianjun Ou, Li Li, Ye Yang, Jingping Zhao, Renrong Wu
Olanzapine is a widely used atypical antipsychotic medication for treatment of schizophrenia and is often associated with serious metabolic abnormalities including weight gain and impaired glucose tolerance. These metabolic side effects are severe clinical problems but the underpinning mechanism remains poorly understood. Recently, growing evidence suggests that Wnt signaling pathway has a critical role in the pathogenesis of schizophrenia and molecular cascades of antipsychotics action, of which Wnt signaling pathway key effector TCF7L2 is strongly associated with glucose homeostasis...
2018: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/29706449/predictors-of-all-cause-discontinuation-of-initial-oral-antipsychotic-medication-in-first-episode-psychosis
#6
Sally Mustafa, Ridha Joober, Martin Lepage, Srividya Iyer, Jai Shah, Ashok Malla
INTRODUCTION: Discontinuation of the initial oral antipsychotic prescribed for a first episode of psychosis (FEP) can derail outcome. Our objective was to examine the rate of and time to all-cause discontinuation of the first antipsychotic prescribed and the factors influencing such discontinuation. METHODS: In a sample of 390 FEP patients, we estimated the rate of and time to discontinuation of the initial antipsychotic over a one-year period. The effects of a number of putative predictors of discontinuation were estimated using regression analyses...
April 26, 2018: Schizophrenia Research
https://www.readbyqxmd.com/read/29699527/collaborative-individualised-lifestyle-interventions-are-acceptable-to-people-with-first-episode-psychosis-a-qualitative-study
#7
Rebecca Pedley, Karina Lovell, Penny Bee, Tim Bradshaw, Judith Gellatly, Kate Ward, Adrine Woodham, Alison Wearden
BACKGROUND: The adverse impact of unhealthy lifestyle choices and the prescription of antipsychotic medications contribute to weight gain, poor cardiovascular health and reduced life expectancy for people with psychosis. The present study aimed to explore the acceptability and perceived outcomes of a lifestyle intervention designed to prevent or reduce weight gain in people with first-episode psychosis. METHODS: This was a qualitative study using a data-driven approach...
April 25, 2018: BMC Psychiatry
https://www.readbyqxmd.com/read/29659460/clozapine-titration-for-people-in-early-psychosis-a-chart-review-and-treatment-guideline
#8
Jacob S Ballon, Hera Ashfaq, Douglas L Noordsy
PURPOSE/BACKGROUND: The use of clozapine, particularly in young people, is often limited by early treatment-emergent adverse effects including drowsiness and lethargy. Concerns about adverse effects, medication adherence, and the need for blood monitoring often impede the use of clozapine in this population, leading to repeated trials of less effective medications. Current clozapine dosing recommendations are based on people further in the course of their illness and thus reflect different responsiveness and sensitivities to antipsychotic medication...
June 2018: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/29620914/effects-of-metformin-on-spatial-and-verbal-memory-in-children-with-asd-and-overweight-associated-with-atypical-antipsychotic-use
#9
Michael G Aman, Jill A Hollway, Jeremy Veenstra-VanderWeele, Benjamin L Handen, Kevin B Sanders, James Chan, Eric Macklin, L Eugene Arnold, Taylor Wong, Cassandra Newsom, Rianne Hastie Adams, Sarah Marler, Naomi Peleg, Evdokia A Anagnostou
OBJECTIVES: Studies in humans and rodents suggest that metformin, a medicine typically used to treat type 2 diabetes, may have beneficial effects on memory. We sought to determine whether metformin improved spatial or verbal memory in children with autism spectrum disorder (ASD) and overweight associated with atypical antipsychotic use. METHODS: We studied the effects of metformin (Riomet® ) concentrate on spatial and verbal memory in 51 youth with ASD, ages 6 through 17 years, who were taking atypical antipsychotic medications, had gained significant weight, and were enrolled in a trial of metformin for weight management...
April 5, 2018: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/29602172/no-differences-in-olanzapine-and-risperidone-related-weight-gain-between-women-and-men-a-meta-analysis-of-short-and-middle-term-treatment
#10
G Schoretsanitis, M Drukker, J Van Os, K R J Schruers, M Bak
OBJECTIVE: A plethora of data deriving from single studies as well as meta-analyses demonstrates that weight gain is associated with the exposure to the majority of antipsychotics (AP). However, potential sex differences have widely evaded the attention of AP treatment trials. It is hypothesised that female patients gain more weight compared with male patients due to their enhanced susceptibility to adverse drug reactions. METHOD: A meta-analysis was conducted using clinical trials of AP that reported weight change separately for female and male patients...
March 30, 2018: Acta Psychiatrica Scandinavica
https://www.readbyqxmd.com/read/29579528/decision-making-capacity-for-treatment-of-psychotic-patients-on-long-acting-injectable-antipsychotic-treatment
#11
Maria Nystazaki, Katerina Pikouli, Eva-Maria Tsapakis, Maria Karanikola, Dimitrios Ploumpidis, Giorgos Alevizopoulos
OBJECTIVE: Providing informed, consent requires patients' Decision-Making Capacity for treatment. We evaluated the Decision Making Capacity of outpatients diagnosed with schizophrenia and schizoaffective disorder on treatment with Long Acting Injectable Antipsychotic medication. METHOD: This is a retrospective, cross-sectional, correlational study conducted at two Depot Clinics in Athens, Greece. Participants included 65 outpatients diagnosed with schizophrenia and schizoaffective disorder on treatment with Long Acting Injectable Antipsychotics...
April 2018: Archives of Psychiatric Nursing
https://www.readbyqxmd.com/read/29559497/antipsychotic-medication-and-type-2-diabetes-and-impaired-glucose-regulation
#12
Clare Whicher, Hermione Clare Price, Richard Ig Holt
Objective There have been concerns about the effects of antipsychotics on weight gain and the development of type 2 diabetes (T2DM). This article aims to provide an up to date review on the evidence addressing this issue and the practical implications for the management of people taking antipsychotics in the context of T2DM. Methods We carried out searches on MEDLINE/PUBMED and the ClinicalTrials.gov website in August 2017 using the terms 'antipsychotic' and 'diabetes' or 'glucose' citing articles published after 2006 preferentially...
March 20, 2018: European Journal of Endocrinology
https://www.readbyqxmd.com/read/29557263/topiramate-mitigates-weight-gain-in-antipsychotic-treated-patients-with-schizophrenia-meta-analysis-of-randomised-controlled-trials
#13
Kah Kheng Goh, Chun-Hsin Chen, Mong-Liang Lu
OBJECTIVE: Weight gain is one of the most challenging issues in patients with schizophrenia treated with antipsychotics. Several meta-analyses have been conducted to review the efficacy of topiramate in reducing weight, however, several issues regarding the methodology had arisen of which make the results remain ambiguous. METHODS: We conducted a meta-analysis of randomised controlled trials about the use of topiramate in patients with schizophrenia for weight reduction...
March 20, 2018: International Journal of Psychiatry in Clinical Practice
https://www.readbyqxmd.com/read/29540664/prebiotic-attenuation-of-olanzapine-induced-weight-gain-in-rats-analysis-of-central-and-peripheral-biomarkers-and-gut-microbiota
#14
Amy Chia-Ching Kao, Sonia Spitzer, Daniel C Anthony, Belinda Lennox, Philip W J Burnet
Olanzapine is an effective antipsychotic drug but since it causes significant weight gain, it is not well tolerated by psychosis patients. The prebiotic, B-GOS® , attenuates metabolic dysfunction in obese subjects, and in rodents, alters central NMDA receptors and may affect serotonin receptors that are relevant in psychosis. We have determined whether B-GOS® influenced olanzapine-associated weight gain and central NMDA and serotonin receptors. Circulating acetate, IL-1β, IL-8 and TNFα, liver acetyl-CoA carboxylase (ACC), white adipose tissue (WAT) acetate receptor GPR43, and specific faecal bacteria genera were also measured to provide mechanistic information...
March 15, 2018: Translational Psychiatry
https://www.readbyqxmd.com/read/29528898/new-findings-in-pharmacogenetics-of-schizophrenia
#15
Clement C Zai, Arun K Tiwari, Gwyneth C Zai, Miriam S Maes, James L Kennedy
PURPOSE OF REVIEW: This review highlights recent advances in the investigation of genetic factors for antipsychotic response and side effects. RECENT FINDINGS: Antipsychotics prescribed to treat psychotic symptoms are variable in efficacy and propensity for causing side effects. The major side effects include tardive dyskinesia, antipsychotic-induced weight gain (AIWG), and clozapine-induced agranulocytosis (CIA). Several promising associations of polymorphisms in genes including HSPG2, CNR1, and DPP6 with tardive dyskinesia have been reported...
May 2018: Current Opinion in Psychiatry
https://www.readbyqxmd.com/read/29519756/effects-of-cannabis-use-on-body-mass-fasting-glucose-and-lipids-during-the-first-12-months-of-treatment-in-schizophrenia-spectrum-disorders
#16
F Scheffler, S Kilian, B Chiliza, L Asmal, L Phahladira, S du Plessis, M Kidd, R M Murray, M Di Forti, S Seedat, R Emsley
While acute cannabis use stimulates appetite, general population studies suggest that chronic use is associated with reduced risk of obesity and other cardiometabolic risk factors. In this study we investigated changes in body mass index (BMI), fasting blood glucose and lipids, and rates of metabolic syndrome risk factors in cannabis users vs. non-users in 109 minimally treated patients with first-episode schizophrenia, schizophreniform or schizo-affective disorder who were treated according to a standardized treatment regime with depot antipsychotic medication over 12 months...
March 6, 2018: Schizophrenia Research
https://www.readbyqxmd.com/read/29503232/potentially-fatal-outcomes-associated-with-clozapine
#17
Kevin J Li, Ronald J Gurrera, Lynn E Delisi
Clozapine has been shown to be the most efficacious therapy for treatment resistant schizophrenia, estimated at one third of all schizophrenia cases. There is significant morbidity and mortality associated with clozapine including risk of agranulocytosis, aspiration pneumonia, bowel ischemia, myocarditis, seizures, and weight gain. Here we present a case of a 62-year-old man with chronic paranoid schizophrenia refractory to numerous antipsychotics who was started on clozapine therapy during an acute inpatient psychiatric admission...
March 1, 2018: Schizophrenia Research
https://www.readbyqxmd.com/read/29496143/considerations-for-optimal-use-of-postmortem-human-brains-for-molecular-psychiatry-lessons-from-schizophrenia
#18
Cynthia Shannon Weickert, Debora A Rothmond, Tertia D Purves-Tyson
Schizophrenia is a disabling disease impacting millions of people around the world, for which there is no known cure. Current antipsychotic treatments for schizophrenia mainly target psychotic symptoms, do little to ameliorate social or cognitive deficits, have side-effects that cause weight gain, and diabetes and 30% of people do not respond. Thus, better therapeutics for schizophrenia aimed at the route biologic changes are needed and discovering the underlying neurobiology is key to this quest. Postmortem brain studies provide the most direct and detailed way to determine the pathophysiology of schizophrenia...
2018: Handbook of Clinical Neurology
https://www.readbyqxmd.com/read/29493378/liraglutide-prevents-metabolic-side-effects-and-improves-recognition-and-working-memory-during-antipsychotic-treatment-in-rats
#19
Ilijana Babic, Ashleigh Gorak, Martin Engel, Dominic Sellers, Paul Else, Ashleigh L Osborne, Nagesh Pai, Xu-Feng Huang, Jessica Nealon, Katrina Weston-Green
BACKGROUND: Antipsychotic drugs (APDs), olanzapine and clozapine, do not effectively address the cognitive symptoms of schizophrenia and can cause serious metabolic side-effects. Liraglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist with anti-obesity and neuroprotective properties. The aim of this study was to examine whether liraglutide prevents weight gain/hyperglycaemia side-effects and cognitive deficits when co-administered from the commencement of olanzapine and clozapine treatment...
May 2018: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/29486513/combination-of-metformin-and-lifestyle-intervention-for-antipsychotic-related-weight-gain-a-meta-analysis-of-randomized-controlled-trials
#20
Wei Zheng, Qing-E Zhang, Dong-Bin Cai, Xin-Hu Yang, Gabor S Ungvari, Chee H Ng, Ren-Rong Wu, Yu-Tao Xiang
INTRODUCTION: Weight gain is a common antipsychotic (AP)-related adverse drug reaction (ADR) that can increase the risk of cardiovascular diseases and premature mortality. This meta-analysis examined the efficacy and tolerability of combining metformin and lifestyle intervention for AP-related weight gain in schizophrenia. METHODS: Randomized controlled trials (RCTs) with meta-analyzable data were searched and retrieved by 2 independent investigators. RevMan software (version 5...
February 27, 2018: Pharmacopsychiatry
keyword
keyword
54097
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"